Black Diamond Therapeutic Q4 EPS $(0.59) Beats $(0.63) Estimate; Cash, Cash Equivalents & Investments Of $122.8M Expected To Be Sufficient To Fund Operations Into Q3 2024
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.63) by 6.35 percent. This is a 16.9 percent increase over losses of $(0.71) per